Eosinophilic esophagitis: Current concepts in diagnosis and management

Saudi J Gastroenterol. 2024 Jul 1;30(4):210-227. doi: 10.4103/sjg.sjg_50_24. Epub 2024 May 16.

Abstract

Eosinophilic esophagitis is an antigen-mediated chronic inflammatory disorder that has risen in incidence and prevalence over the past 2 decades. The clinical presentation is variable and consists of mainly esophageal symptoms such as dysphagia, heartburn, food impaction, and vomiting. Current management relies on dietary elimination, proton-pump inhibitors, and topical corticosteroids with different response rates and relapses after treatment discontinuation. With a better understanding of the underlying pathophysiology, many molecules emerged recently as targeted treatment including dupilumab (IL4/IL13 blocker), as the first FDA-approved biological treatment, which has changed the management paradigm.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Eosinophilic Esophagitis* / diagnosis
  • Eosinophilic Esophagitis* / epidemiology
  • Eosinophilic Esophagitis* / therapy
  • Humans
  • Proton Pump Inhibitors* / therapeutic use

Substances

  • Proton Pump Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Adrenal Cortex Hormones
  • dupilumab